Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R T Dorr

Showing results (21-30 of 156) with videos related to

Pageof 16
Sort By:
Cancer Treatment Reports|May 1, 1983
Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouseR T Dorr, D S Alberts
Current Medicinal Chemistry|September 25, 2012
Chemistry and pharmacology of imexon and related cyanoaziridinesW A Remers, R T Dorr
Medical Oncology and Tumor Pharmacotherapy|January 1, 1988
Quantitation of ellipsoid tumor areas using a circumferential measuring deviceR T Dorr, D S Alberts
Journal of the National Cancer Institute|January 1, 1985
Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouseR T Dorr, D S Alberts
Seminars in Oncology|May 29, 1999
Dosing considerations with amifostine: a review of the literature and clinical experienceR T Dorr, B C Holmes
Anticancer Research|September 1, 1994
Effect of doxorubicin on glutathione and glutathione-dependent enzymes in cultured rat heart cellsN S Paranka, R T Dorr
Cancer Chemotherapy and Pharmacology|January 1, 1991
Modulation of mitomycin C-induced multidrug resistance in vitroR T Dorr, J D Liddil
Advances in Experimental Medicine and Biology|January 1, 1991
Biochemical effects and toxicity of mitoxantrone in cultured heart cellsN G Shipp, R T Dorr
Cancer Treatment Reports|November 1, 1981
Pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for beta-adrenergic compoundsR T Dorr, D S Alberts
Journal of Cancer Research and Clinical Oncology|January 1, 1989
H2-antagonists and carmustineR T Dorr, M J Soble
Pageof 16

Showing results (21-30 of 156) with videos related to

Sort By:
Pageof 16
Cancer Treatment Reports|May 1, 1983
Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouseR T Dorr, D S Alberts
Current Medicinal Chemistry|September 25, 2012
Chemistry and pharmacology of imexon and related cyanoaziridinesW A Remers, R T Dorr
Medical Oncology and Tumor Pharmacotherapy|January 1, 1988
Quantitation of ellipsoid tumor areas using a circumferential measuring deviceR T Dorr, D S Alberts
Journal of the National Cancer Institute|January 1, 1985
Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouseR T Dorr, D S Alberts
Seminars in Oncology|May 29, 1999
Dosing considerations with amifostine: a review of the literature and clinical experienceR T Dorr, B C Holmes
Anticancer Research|September 1, 1994
Effect of doxorubicin on glutathione and glutathione-dependent enzymes in cultured rat heart cellsN S Paranka, R T Dorr
Cancer Chemotherapy and Pharmacology|January 1, 1991
Modulation of mitomycin C-induced multidrug resistance in vitroR T Dorr, J D Liddil
Advances in Experimental Medicine and Biology|January 1, 1991
Biochemical effects and toxicity of mitoxantrone in cultured heart cellsN G Shipp, R T Dorr
Cancer Treatment Reports|November 1, 1981
Pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for beta-adrenergic compoundsR T Dorr, D S Alberts
Journal of Cancer Research and Clinical Oncology|January 1, 1989
H2-antagonists and carmustineR T Dorr, M J Soble
Pageof 16